7 recruiting, 1 active not recruiting. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 7, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Immune-related Adverse Event: new trials by email Literature Review of Immune-related Adverse Event trials Research Report on Immune-related Adverse Event
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy Mycophenolate Mofetil plus prednisone - Immune-mediated Hepatitis, Immune-related Adverse Event | Phase 2 | Recruiting | Fox Chase Cancer Center | 31 | 2026-07-23 | 2026-09-17 |
| Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care, Arm 1- Usual care - Pneumonitis, Immune-related Adverse Event | Phase 2 | Recruiting | AHS Cancer Control Alberta | 94 | 2026-02-10 | 2026-08-07 |
| Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) Mesalamine - Immune-related Adverse Event, Diarrhea | Phase 2 | Recruiting | AHS Cancer Control Alberta | 20 | 2024-08-20 | 2025-06-27 |
| SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] - Endometrial Cancer Stage I, Mmr Deficiency | Phase 2 | Recruiting | Queensland Centre for Gynaecological Cancer | 10 | 2024-08-01 | 2024-12-03 |
| Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis Adalimumab, Prednisone - Inflammatory Arthritis, Immune-related Adverse Event | Phase 2 | Recruiting | Tom Appleton | 30 | 2024-04-15 | 2026-03-03 |
| Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody - Melanoma, Immune-related Adverse Event | Phase 2 | Recruiting | Sun Yat-sen University | 55 | 2023-05-30 | 2026-06-12 |
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis Infliximab, Methylprednisolone, Prednisone - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | Massachusetts General Hospital | 42 | 2020-08-31 | 2026-10-29 |
Colitis (2) · Diarrhea (2) · Melanoma (2) · Arthritis (1) · Drug-Related Side Effects and Adverse Reactions (1) · Endometrial Neoplasms (1) · Pneumonia (1) · Skin Neoplasms (1) · Turcot syndrome (1)
Neoplasms (3) · Neoplasms by Site (3) · Colonic Diseases (2) · Digestive System Diseases (2) · Gastroenteritis (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2)
Prednisone (3) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Glucocorticoids (1) · Infliximab (1) · Mesalamine (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Mycophenolic Acid (1) · Thymalfasin (1) · dostarlimab (1) · vedolizumab (1)
AHS Cancer Control Alberta (3) · Fox Chase Cancer Center (1) · Massachusetts General Hospital (1) · Queensland Centre for Gynaecological Cancer (1) · Sun Yat-sen University (1) · Tom Appleton (1)
Canada (4) · United States (2) · Australia (1) · China (1)
Andreas Obermair, Professor (1) · Dandan Li, PhD (1) · Jingjing Zhao, PhD (1) · Long Nguyen, MD, MS (1) · Matthew Zibelman, MD (1) · Penghui Zhou, PhD (1) · Xiaoshi Zhang, phD (1) · Ya Ding, PhD (1)
PMID 10741392, PMID 16741252, PMID 20194853, PMID 23045967, PMID 39955187